Introduction
HIV-infected women are at increased risk of human papillomavirus (HPV)-associated invasive cervical carcinoma (ICC), 1 an AIDS-defining illness and vaccine-preventable disease. Despite routine screening in Brazil, the Instituto Nacional de Câncer estimated 15,590 new ICC cases in 2014, with a 33% fatality rate. High-risk HPV (HR-HPV) genotypes 16 and 18 are associated with 70% of ICC cases worldwide, while the other 13 HR-HPV genotypes account for the remaining cases. 2 The HPV vaccine was proposed as a method to effectively reduce ICC prevalence at the population level. Three US Food and Drug Administration (FDA)-approved HR-HPV vaccines are currently available: the bivalent, quadrivalent, and nine-valent vaccines. The bivalent and quadrivalent vaccines protect against only HPV 16 and 18 of the HR-HPV genotypes, and the impact of these vaccines on non-16/18 HR-HPV genotypes remains unclear. [3] [4] [5] 
Statistical analysis
A descriptive analysis of the following was performed yearly (2006-2012), using clinical data and cervical specimens closest to the July 1 marker of the mid-year: current age, CD4+ T-cell count, HIV-1 viral load, cervical cytology, cervical treatments, and prevalences of the 15 HR-HPV genotypes. The clinical data for 12  15  12  18  12  13  7  6  11  7  8  31  11  7  3  7  8  9  12  33  1  7  5  5  6  4  3  35  6  7  9  9  11  13  13  39  10  3  4  6  7  7  12  45  4  6  5  7  5  4  10  51  7  5  5  8  13  15  7  52  6  7  9  6  6  8  6  56  10  7  4  5  5  5  11  58  25  13  12  19  20  26  21  59  2  7  8  7  11  19  24  68  24  8  5  5  8  9  10  73  0  4  5  4  5  3  7  82  1  2  2  1  3  2 each year reflect those of the participants who contributed an HPV sample in that given year. Women who underwent hysterectomies were excluded from the analysis in the years post-procedure. Odds ratios (OR) and 95% confidence intervals (CI) for HPV positivity were estimated for each genotype using generalized estimating equation models with an exchangeable matrix to account for patient clustering. The year was the independent predictor, with 2006 as the reference category. The final model was adjusted for age as a continuous variable, given the inverse association between age and HPV positivity. 8 Bonferroni-adjusted p-values were calculated to account for multiple comparisons. The statistical analysis was performed using R version 3.01, with statistical significance defined using a two-sided a < 0.05.
Results
Five hundred ninety-one women met the inclusion criteria, with one excluded for prior hysterectomy (final N = 590). Table 1 describes the characteristics and annual HR-HPV genotype prevalences by year (2006) (2007) (2008) (2009) (2010) (2011) (2012) . Table 2 
Discussion
In this cohort of 590 HIV-positive women, the high prevalences of HPV 58 and 59 are concerning, given that HPV 58 is associated with pre-malignant cervical lesions among HIV-uninfected women in Brazil, 9, 10 and both genotypes are commonly identified in HIV-positive women worldwide. 2 Additionally, neither the bivalent nor the quadrivalent vaccine cover HPV 58 and 59, leading to questions regarding their efficacy against non-16/18 genotypes. 4, 5 This study has both strengths and limitations. While it is unclear which factors influenced the fluctuating HPV prevalences, current clinical and cervical data remained relatively unchanged. HPV prevalences were analyzed over a 7-year period, compared to most studies utilizing a single time point. Additionally, the present study is one of the largest HPV/HIV co-infection studies in the Americas. However, the individual sample sizes for each HPV genotype are relatively small, and additional studies with larger sample sizes and longer follow-up are needed to further explore temporal trends in HR-HPV prevalences.
Continued monitoring of HR-HPV epidemiology and further investigations into the effects of HPV vaccination on non-16/18 HR-HPV genotypes are needed to optimize HPV vaccine recommendations for HIV-infected women in Brazil. Table 2 Odds 
